Literature DB >> 8433573

Laminin distribution in developing glomerular basement membranes.

D R Abrahamson1, P L St John.   

Abstract

The renal glomerular basement membrane (GMB) separates two distinctly different cell layers: the vascular endothelium, and visceral epithelial podocytes. When initial vascularization of the forming glomerulus takes place during nephrogenesis, the early GBM forms by fusion of a dual basement membrane between endothelial cells and podocytes. As glomerular capillary loops blossom, newly synthesized basement membrane segments derived from podocytes are then inserted or spliced into the fused GBM. The molecular processes accounting for either basement membrane fusion or splicing are unresolved. Using monoclonal anti-mouse laminin antibodies (mAbs) against the end of the laminin long arm (5D3), we have shown in adult mice that peripheral loop GBM is only weakly immunoreactive but the mesangial matrix and tubular basement membrane (TBM) is intensely positive. In contrast, mAbs against domains in the center of the laminin cross only label TBMs and mesangial matrices of mature mice and GBMs are negative. Immunofluorescence microscopy of neonatal mouse kidneys showed, however, that anti-laminin mAbs brightly labeled developing GBMs of glomeruli undergoing initial vascularization and capillary loop formation. Post-fusion GBMs of maturing stage glomeruli became unreactive for most anti-laminin mAbs but remained positive for 5D3. Our results therefore show that some GBM laminin epitopes are transiently expressed during glomerular development. These changes in GBM immunoreactivities may reflect proteolytic processing during basement membrane fusion and splicing, or temporally controlled synthesis of different laminin isoforms.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8433573     DOI: 10.1038/ki.1993.13

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

1.  Synergistic activation of the rat laminin gamma1 chain promoter by the gut-enriched Kruppel-like factor (GKLF/KLF4) and Sp1.

Authors:  Yuji Higaki; Daniel Schullery; Yasunobu Kawata; Maria Shnyreva; Christine Abrass; Karol Bomsztyk
Journal:  Nucleic Acids Res       Date:  2002-06-01       Impact factor: 16.971

2.  Two Specific Sulfatide Species Are Dysregulated during Renal Development in a Mouse Model of Alport Syndrome.

Authors:  Megan M Gessel; Jeffrey M Spraggins; Paul A Voziyan; Dale R Abrahamson; Richard M Caprioli; Billy G Hudson
Journal:  Lipids       Date:  2019-06-13       Impact factor: 1.880

3.  Localization of extracellular matrix components in congenital nephrotic syndromes.

Authors:  A G Nerlich; I Wiest; E D Schleicher
Journal:  Pediatr Nephrol       Date:  1995-04       Impact factor: 3.714

4.  Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney.

Authors:  L K Lee; T W Meyer; A S Pollock; D H Lovett
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

5.  The laminin alpha chains: expression, developmental transitions, and chromosomal locations of alpha1-5, identification of heterotrimeric laminins 8-11, and cloning of a novel alpha3 isoform.

Authors:  J H Miner; B L Patton; S I Lentz; D J Gilbert; W D Snider; N A Jenkins; N G Copeland; J R Sanes
Journal:  J Cell Biol       Date:  1997-05-05       Impact factor: 10.539

6.  Kidney organoids recapitulate human basement membrane assembly in health and disease.

Authors:  Mychel R P T Morais; Pinyuan Tian; Craig Lawless; Syed Murtuza-Baker; Louise Hopkinson; Steven Woods; Aleksandr Mironov; David A Long; Daniel P Gale; Telma M T Zorn; Susan J Kimber; Roy Zent; Rachel Lennon
Journal:  Elife       Date:  2022-01-25       Impact factor: 8.713

7.  A novel biomarker of laminin turnover is associated with disease progression and mortality in chronic kidney disease.

Authors:  Signe Holm Nielsen; Daniel Guldager Kring Rasmussen; Susanne Brix; Anthony Fenton; Mark Jesky; Charles J Ferro; Morten Karsdal; Federica Genovese; Paul Cockwell
Journal:  PLoS One       Date:  2018-10-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.